Windlas BiotechNSE:WINDLAS +1.24%89 Days Inventory is 38.36 as of Mar. 2026, which is 36% below its 10-year median of 59.66. GuruFocus rates NSE:WINDLAS with a GF Score™ of 89/100 and a GF Value™ of ₹935.87 (Fairly Valued). The stock has 1 warning sign investors should review. Among 918 Drug Manufacturers companies, Windlas Biotech ranks better than 94.99% on this metric.
The historical rank and industry rank for Windlas Biotech's Days Inventory or its related term are showing as below:
NSE:WINDLAS'
s Days Inventory Range Over the Past 10 Years
Min: 36.19 Med: 59.66 Max: 74.83
Current: 46.62
During the past 8 years, Windlas Biotech's highest Days Inventory was 74.83. The lowest was 36.19. And the median was 59.66.
NSE:WINDLAS's Days Inventory is ranked better than 94.99% of 918
companies
in the Drug Manufacturers industry
Industry Median: 164.43
vs NSE:WINDLAS: 46.62
Windlas Biotech's Days Inventory
declined
from Mar. 2025 (59.32) to Mar. 2026 (38.36).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Windlas Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 was 2.38.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Windlas Biotech's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.26.
Windlas Biotech (NSE:WINDLAS) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Windlas Biotech's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Windlas Biotech's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Windlas Biotech Days Inventory Related Terms
Windlas Biotech Days Inventory Historical Data
* Premium members only.
The historical data trend for Windlas Biotech's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:WINDLAS vs ZTS, UTHR: Days Inventory Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Windlas Biotech's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Windlas Biotech Days Inventory vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Windlas Biotech's Days Inventory distribution charts can be found below:
* The bar in red indicates where Windlas Biotech's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Windlas Biotech (NSE:WINDLAS) has a Days Inventory of 38.36 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Windlas Biotech and its competitors. This is 36% below median its historical median of 59.66. Over the past decade, Windlas Biotech's Days Inventory has ranged from 36.19 to 74.83. According to the industry distribution chart, Windlas Biotech ranks #46 out of 918 companies in the Drug Manufacturers industry, placing it in the top 5%.
Is Windlas Biotech's Days Inventory too high?
Windlas Biotech's current Days Inventory of 38.36 is 36% below median its 10-year median of 59.66. Over the past 10 years, this metric has ranged from a low of 36.19 to a high of 74.83. The Drug Manufacturers industry median Days Inventory is 164.43. Windlas Biotech's value of 38.36 is 76.7% below this industry median. Based on the distribution chart, Windlas Biotech ranks #46 out of 918 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Windlas Biotech has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Windlas Biotech's Days Inventory compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Windlas Biotech ranks #46 out of 918 companies for Days Inventory. This places Windlas Biotech in the top 5% of its industry — outperforming the majority of peers. The industry median Days Inventory is 164.43. Windlas Biotech's value of 38.36 is 76.7% below this benchmark. Historically, Windlas Biotech's own Days Inventory has ranged from 36.19 to 74.83 over the past decade. While the company's 10-year median is 59.66 vs. the industry median of 164.43, Windlas Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Drug Manufacturers company?
The median Days Inventory among Drug Manufacturers companies is 164.43, based on 918 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Windlas Biotech's current Days Inventory of 38.36 is 76.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Windlas Biotech and its competitors. For the Drug Manufacturers industry, the median Days Inventory is 164.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Windlas Biotech's current Days Inventory is 38.36, which is 36% below median its own 10-year median of 59.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Windlas Biotech stock overvalued right now?
Based on GuruFocus' analysis, Windlas Biotech (NSE:WINDLAS) is currently considered Fairly Valued. The stock's GF Value™ is ₹935.87, compared to a current price of ₹871.90 — trading 6.8% below its estimated fair value. The current Days Inventory is 38.36, which is 36% below median its 10-year median of 59.66 and 76.7% below the Drug Manufacturers industry median of 164.43. Windlas Biotech's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Windlas Biotech (NSE:WINDLAS), the current Days Inventory is 38.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Windlas Biotech (NSE:WINDLAS) Overvalued in 2026?
Based on GuruFocus' analysis, Windlas Biotech stock appears to be undervalued.
The current stock price of ₹871.90 is trading 6.8% below its estimated GF Value™ of ₹935.87.
GuruFocus considers Windlas Biotech to be Fairly Valued.
Key valuation signals for NSE:WINDLAS:
Days Inventory: 38.36 (36% below median its 10-year median of 59.66)
GF Value™: ₹935.87 vs. price of ₹871.90 (6.8% below fair value)
Industry Position: 76.7% below the Drug Manufacturers median (#46 of 918)
No single metric tells the full story. See the NSE:WINDLAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Windlas Biotech Ltd is a pharmaceutical formulation contract development and manufacturing organization. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
89GF Score
Get the complete analysis for NSE:WINDLAS
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:WINDLAS has been successfully added to your 
